Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Not Applicable
1 (33.3%)CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer
Not Applicable
Not yet recruiting
- Conditions
- Metastatic CancerUnresectable Solid Tumor
- Interventions
- Drug: [18F]CSB-321
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Cytosite Biopharma Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT07057349
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Study to Evaluate the Safety and Dosimetry of [68Ga]-NOTA-hGZP (CSB-111) PET Imaging in Healthy Human Volunteers.
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Cytosite Biopharma Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05285696
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
Phase 1
Recruiting
- Conditions
- Solid Tumor, Unspecified, AdultLymphoma
- Interventions
- Drug: Single Arm
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Cytosite Biopharma Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04169321
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇨🇳Chang-Gung Memorial Hospital, Taoyuan City, Guishan, Taiwan
News
No news found